Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating income | — | -$2.82M |
| Net income | — | $5.94M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | — | -$539K |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $1.35K | $6.14K |
| Total assets | $551K | $240M |
| Total liabilities | $796K | $7.28M |
| Shareholders' equity | -$245K | -$7.26M |
| Retained earnings | -$280K | -$7.27M |
| Shares (wtd avg diluted) | 9.86M | 10.7M |
Every figure is extracted from Drugs Made In America Acquisition Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.